Decitabine at DNMT1-depleting concentrations, alone or in combination with teriflunomide or venetoclax, did not activate apoptosis in NHSPC compared with camptothecin positive control. CD34⁺ NHSPC isolated from umbilical cord blood were treated with vehicle, camptothecin 0.25μM, decitabine 0.5μM, venetoclax 1μM, teriflunomide 10μM, or combinations, as indicated. Measurements were performed after 24 hours of treatment. Independent biological replicates. (A) DNMT1 protein and DNA content (DAPI) was measured by flow cytometry in vehicle-, camptothecin-, and decitabine-treated cells. Fluorescence intensities. (B) Cell viability was measured by automated counter. (C) Cell count was measured by automated counter. (D) Apoptosis was measured by flow cytometry for Annexin V and PI staining. Bar graph shows Annexin V, MFI. (E) Apoptosis was also measured by fluorescence assay for caspase 3 and 7 activation. Technical triplicate from first biological replicate, similar results from second biological replicate. Significant increase observed only with camptothecin positive control, P values are from unpaired 2-sided t test. Campto, camptothecin; DAPI, 4′,6-diamidino-2-phenylindole; Dec, decitabine; MFI, median fluorescence intensity; PI, propidium iodide; Teri, teriflunomide; Veh, vehicle; Ven, venetoclax.